Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS1009-212 TPIP PH-ILD Open-Label Extension
2023-505540-19-00Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of treprostinil palmitil in pulmonary hypertension associated with interstitial lung disease (PH-ILD), sponsored by Insmed Incorporated. Primary endpoint: Frequency and severity of TEAEs during the study. Started Apr 2024; status: completed.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2023-505540-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505540-19-00.